| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiomyopathies | 23 | 2026 | 316 | 5.060 |
Why?
|
| Amyloid Neuropathies, Familial | 19 | 2026 | 53 | 4.520 |
Why?
|
| Heart Failure | 52 | 2026 | 1501 | 3.820 |
Why?
|
| Heart-Assist Devices | 42 | 2025 | 917 | 3.360 |
Why?
|
| Amyloidosis | 16 | 2026 | 136 | 2.970 |
Why?
|
| Prealbumin | 14 | 2026 | 47 | 1.820 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 9 | 2026 | 31 | 1.610 |
Why?
|
| Hemodynamics | 19 | 2025 | 746 | 1.560 |
Why?
|
| Heart Transplantation | 10 | 2026 | 873 | 1.160 |
Why?
|
| Ventricular Function, Left | 15 | 2025 | 540 | 1.150 |
Why?
|
| Echocardiography | 12 | 2026 | 783 | 1.110 |
Why?
|
| Pulmonary Wedge Pressure | 10 | 2021 | 123 | 0.840 |
Why?
|
| Heart Ventricles | 10 | 2024 | 664 | 0.720 |
Why?
|
| Cardiac Catheterization | 10 | 2019 | 307 | 0.690 |
Why?
|
| Middle Aged | 65 | 2026 | 29494 | 0.660 |
Why?
|
| Heart Valve Diseases | 3 | 2024 | 103 | 0.660 |
Why?
|
| Diflunisal | 1 | 2020 | 1 | 0.650 |
Why?
|
| Male | 72 | 2026 | 47195 | 0.610 |
Why?
|
| Aged | 51 | 2026 | 21824 | 0.600 |
Why?
|
| Humans | 95 | 2026 | 98223 | 0.590 |
Why?
|
| Intra-Aortic Balloon Pumping | 5 | 2024 | 100 | 0.590 |
Why?
|
| Female | 69 | 2026 | 51685 | 0.550 |
Why?
|
| Retrospective Studies | 34 | 2026 | 11031 | 0.530 |
Why?
|
| Benzoxazoles | 3 | 2026 | 4 | 0.490 |
Why?
|
| Treatment Outcome | 23 | 2026 | 9750 | 0.390 |
Why?
|
| RNA, Small Interfering | 2 | 2026 | 565 | 0.390 |
Why?
|
| Prosthesis Implantation | 3 | 2019 | 134 | 0.380 |
Why?
|
| Prospective Studies | 16 | 2025 | 4815 | 0.380 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2021 | 133 | 0.380 |
Why?
|
| Postoperative Complications | 7 | 2026 | 2687 | 0.380 |
Why?
|
| Benzoic Acid | 3 | 2026 | 3 | 0.360 |
Why?
|
| Magnetic Resonance Imaging, Cine | 4 | 2026 | 152 | 0.350 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2026 | 62 | 0.350 |
Why?
|
| Transplant Recipients | 2 | 2025 | 182 | 0.340 |
Why?
|
| Immunoglobulin Light Chains | 3 | 2026 | 66 | 0.340 |
Why?
|
| Graft Rejection | 3 | 2026 | 1186 | 0.340 |
Why?
|
| Prognosis | 12 | 2026 | 4126 | 0.330 |
Why?
|
| Pyrazoles | 3 | 2026 | 160 | 0.330 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2024 | 264 | 0.310 |
Why?
|
| Peptide Fragments | 3 | 2026 | 480 | 0.310 |
Why?
|
| Shock, Cardiogenic | 2 | 2021 | 184 | 0.300 |
Why?
|
| Coronary Artery Bypass | 3 | 2020 | 231 | 0.300 |
Why?
|
| Azithromycin | 1 | 2009 | 16 | 0.290 |
Why?
|
| Drug Hypersensitivity | 1 | 2009 | 38 | 0.280 |
Why?
|
| Predictive Value of Tests | 9 | 2026 | 1784 | 0.280 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2024 | 179 | 0.280 |
Why?
|
| Aged, 80 and over | 9 | 2026 | 7409 | 0.280 |
Why?
|
| Myocarditis | 1 | 2009 | 61 | 0.270 |
Why?
|
| Echocardiography, Doppler | 3 | 2018 | 137 | 0.270 |
Why?
|
| Biomarkers | 8 | 2026 | 2020 | 0.270 |
Why?
|
| Pacemaker, Artificial | 2 | 2020 | 119 | 0.260 |
Why?
|
| Thromboembolism | 2 | 2018 | 123 | 0.260 |
Why?
|
| Device Removal | 2 | 2019 | 170 | 0.260 |
Why?
|
| Thrombosis | 2 | 2020 | 318 | 0.260 |
Why?
|
| RNAi Therapeutics | 1 | 2026 | 3 | 0.250 |
Why?
|
| Waiting Lists | 2 | 2025 | 237 | 0.240 |
Why?
|
| Hemorrhage | 2 | 2018 | 297 | 0.240 |
Why?
|
| Hematology | 1 | 2026 | 37 | 0.240 |
Why?
|
| Stroke Volume | 4 | 2025 | 464 | 0.230 |
Why?
|
| Survival Rate | 7 | 2026 | 2050 | 0.230 |
Why?
|
| Cannula | 4 | 2019 | 55 | 0.230 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2018 | 244 | 0.230 |
Why?
|
| Body Composition | 1 | 2026 | 88 | 0.220 |
Why?
|
| Follow-Up Studies | 9 | 2026 | 4041 | 0.220 |
Why?
|
| Heart Function Tests | 2 | 2018 | 29 | 0.220 |
Why?
|
| Double-Blind Method | 5 | 2026 | 1787 | 0.210 |
Why?
|
| Ventricular Function, Right | 3 | 2025 | 146 | 0.210 |
Why?
|
| Cardiotonic Agents | 2 | 2019 | 92 | 0.210 |
Why?
|
| Cardiac Output | 3 | 2022 | 142 | 0.210 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2017 | 339 | 0.200 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2023 | 14 | 0.200 |
Why?
|
| Atrioventricular Block | 1 | 2023 | 33 | 0.190 |
Why?
|
| Registries | 2 | 2026 | 1127 | 0.190 |
Why?
|
| Central Venous Pressure | 2 | 2020 | 27 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 880 | 0.190 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2025 | 161 | 0.190 |
Why?
|
| Anticoagulants | 4 | 2019 | 484 | 0.190 |
Why?
|
| Risk Factors | 9 | 2026 | 6269 | 0.180 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2023 | 108 | 0.180 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 62 | 0.180 |
Why?
|
| Mononeuropathies | 1 | 2022 | 8 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2025 | 243 | 0.180 |
Why?
|
| Body Mass Index | 1 | 2026 | 867 | 0.180 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2023 | 192 | 0.170 |
Why?
|
| Aortic Rupture | 1 | 2022 | 53 | 0.170 |
Why?
|
| Time Factors | 8 | 2025 | 5573 | 0.170 |
Why?
|
| Adult | 19 | 2026 | 29548 | 0.170 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2022 | 103 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2026 | 477 | 0.160 |
Why?
|
| Aftercare | 1 | 2021 | 92 | 0.160 |
Why?
|
| Lactic Acid | 1 | 2021 | 95 | 0.160 |
Why?
|
| Arterial Pressure | 2 | 2018 | 43 | 0.160 |
Why?
|
| Risk Assessment | 4 | 2026 | 2598 | 0.160 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 1017 | 0.160 |
Why?
|
| Rare Diseases | 1 | 2020 | 74 | 0.160 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2020 | 27 | 0.150 |
Why?
|
| Mathematical Concepts | 1 | 2020 | 18 | 0.150 |
Why?
|
| Heart | 2 | 2023 | 527 | 0.150 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 82 | 0.150 |
Why?
|
| Electric Impedance | 1 | 2020 | 118 | 0.150 |
Why?
|
| Pulmonary Artery | 2 | 2021 | 342 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 1098 | 0.150 |
Why?
|
| Sternotomy | 1 | 2019 | 25 | 0.140 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 108 | 0.140 |
Why?
|
| Remote Sensing Technology | 1 | 2018 | 10 | 0.140 |
Why?
|
| Assisted Circulation | 1 | 2018 | 16 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 547 | 0.140 |
Why?
|
| Counterpulsation | 1 | 2018 | 21 | 0.140 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 184 | 0.140 |
Why?
|
| Testosterone | 1 | 2019 | 265 | 0.140 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2018 | 57 | 0.140 |
Why?
|
| Enoxaparin | 1 | 2018 | 27 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2018 | 158 | 0.130 |
Why?
|
| Octreotide | 1 | 2018 | 32 | 0.130 |
Why?
|
| Patient Readmission | 2 | 2019 | 426 | 0.130 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2019 | 96 | 0.130 |
Why?
|
| Thermodilution | 1 | 2017 | 18 | 0.130 |
Why?
|
| Cohort Studies | 6 | 2022 | 3217 | 0.130 |
Why?
|
| Endothelium, Vascular | 2 | 2010 | 440 | 0.130 |
Why?
|
| Ambulatory Care | 1 | 2018 | 202 | 0.130 |
Why?
|
| Secondary Prevention | 1 | 2018 | 185 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2019 | 391 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 286 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 304 | 0.120 |
Why?
|
| Catheter Ablation | 1 | 2020 | 385 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2018 | 269 | 0.120 |
Why?
|
| Defibrillators, Implantable | 1 | 2018 | 192 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2020 | 448 | 0.110 |
Why?
|
| Serotonin | 1 | 2016 | 211 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 341 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 337 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1751 | 0.110 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1234 | 0.110 |
Why?
|
| Gadolinium | 2 | 2026 | 95 | 0.100 |
Why?
|
| Ventricular Remodeling | 2 | 2025 | 108 | 0.100 |
Why?
|
| Incidence | 4 | 2021 | 1786 | 0.100 |
Why?
|
| Hospitalization | 1 | 2019 | 986 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 942 | 0.100 |
Why?
|
| Carney Complex | 1 | 2012 | 3 | 0.090 |
Why?
|
| Prosthesis Design | 3 | 2019 | 309 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 813 | 0.090 |
Why?
|
| Hospital Mortality | 2 | 2019 | 523 | 0.090 |
Why?
|
| Physicians | 1 | 2019 | 685 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 921 | 0.090 |
Why?
|
| Lung | 1 | 2018 | 1408 | 0.090 |
Why?
|
| Electrocardiography | 2 | 2015 | 528 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 391 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2026 | 1944 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2025 | 2002 | 0.080 |
Why?
|
| Recurrence | 3 | 2018 | 1261 | 0.080 |
Why?
|
| Decision Trees | 1 | 2010 | 63 | 0.080 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2010 | 66 | 0.080 |
Why?
|
| Causality | 1 | 2010 | 86 | 0.080 |
Why?
|
| Diuretics | 1 | 2010 | 78 | 0.080 |
Why?
|
| Vasoconstrictor Agents | 1 | 2010 | 71 | 0.070 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 99 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2026 | 2789 | 0.070 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2009 | 56 | 0.070 |
Why?
|
| Prevalence | 2 | 2024 | 1391 | 0.070 |
Why?
|
| Azathioprine | 1 | 2009 | 129 | 0.070 |
Why?
|
| Prednisone | 1 | 2009 | 251 | 0.070 |
Why?
|
| Fibrinolytic Agents | 1 | 2010 | 244 | 0.070 |
Why?
|
| Equipment Failure | 2 | 2018 | 119 | 0.060 |
Why?
|
| Aortic Valve | 2 | 2021 | 258 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 763 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2009 | 371 | 0.060 |
Why?
|
| Comorbidity | 2 | 2020 | 1033 | 0.060 |
Why?
|
| Recovery of Function | 2 | 2019 | 372 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1569 | 0.060 |
Why?
|
| Caribbean Region | 1 | 2025 | 28 | 0.060 |
Why?
|
| Disease Progression | 2 | 2021 | 1612 | 0.060 |
Why?
|
| Amyloidosis, Familial | 1 | 2023 | 2 | 0.050 |
Why?
|
| Amyloid | 1 | 2024 | 104 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 195 | 0.050 |
Why?
|
| Tricuspid Valve | 1 | 2023 | 95 | 0.050 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 2022 | 8 | 0.050 |
Why?
|
| Technetium | 1 | 2022 | 21 | 0.050 |
Why?
|
| Diphosphates | 1 | 2022 | 15 | 0.050 |
Why?
|
| Thorax | 1 | 2023 | 77 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 271 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2026 | 686 | 0.040 |
Why?
|
| Graft Survival | 1 | 2026 | 994 | 0.040 |
Why?
|
| ROC Curve | 1 | 2024 | 793 | 0.040 |
Why?
|
| Algorithms | 1 | 2010 | 2001 | 0.040 |
Why?
|
| Propensity Score | 1 | 2022 | 216 | 0.040 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2021 | 24 | 0.040 |
Why?
|
| Myocardium | 1 | 2024 | 578 | 0.040 |
Why?
|
| Axillary Artery | 1 | 2020 | 12 | 0.040 |
Why?
|
| Heart Atria | 1 | 2022 | 255 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 265 | 0.040 |
Why?
|
| Aorta | 1 | 2021 | 275 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 308 | 0.040 |
Why?
|
| Hyponatremia | 1 | 2020 | 31 | 0.040 |
Why?
|
| Euthyroid Sick Syndromes | 1 | 2019 | 11 | 0.040 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2020 | 67 | 0.040 |
Why?
|
| Endocrine System Diseases | 1 | 2019 | 26 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2023 | 581 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2020 | 295 | 0.040 |
Why?
|
| Hyperthyroidism | 1 | 2019 | 77 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 139 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 81 | 0.040 |
Why?
|
| Heparin | 1 | 2019 | 182 | 0.040 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 61 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 523 | 0.040 |
Why?
|
| Liver | 1 | 2023 | 1230 | 0.040 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 232 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 381 | 0.030 |
Why?
|
| Operative Time | 1 | 2019 | 176 | 0.030 |
Why?
|
| United States | 2 | 2025 | 8252 | 0.030 |
Why?
|
| Coronary Circulation | 1 | 2018 | 97 | 0.030 |
Why?
|
| Contrast Media | 1 | 2023 | 1013 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 63 | 0.030 |
Why?
|
| Thyrotropin | 1 | 2019 | 328 | 0.030 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 38 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2018 | 165 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2018 | 192 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2019 | 269 | 0.030 |
Why?
|
| Neutropenia | 1 | 2018 | 211 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 125 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2010 | 720 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 660 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 359 | 0.030 |
Why?
|
| Thyroxine | 1 | 2019 | 411 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 721 | 0.030 |
Why?
|
| Equipment Safety | 1 | 2016 | 29 | 0.030 |
Why?
|
| Hypothyroidism | 1 | 2019 | 299 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 817 | 0.030 |
Why?
|
| Illinois | 1 | 2018 | 524 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 194 | 0.030 |
Why?
|
| Reoperation | 1 | 2019 | 730 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 118 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2026 | 2673 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 197 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1528 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 608 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 278 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 906 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 158 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 425 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1009 | 0.030 |
Why?
|
| Chicago | 1 | 2019 | 1519 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1194 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 579 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 913 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1946 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2026 | 3611 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 1142 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 643 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 1972 | 0.020 |
Why?
|
| Stroke | 1 | 2020 | 1167 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 3030 | 0.020 |
Why?
|
| Mutation | 1 | 2022 | 4408 | 0.020 |
Why?
|
| Brachial Artery | 1 | 2010 | 37 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2010 | 67 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 229 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 988 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 10127 | 0.010 |
Why?
|